Melissa L. Johnson, MD

Articles

Dr Johnson on the Efficacy of RMC-6236 in KRAS-Mutant NSCLC

November 28th 2023

Melissa L. Johnson, MD, discusses the preliminary efficacy findings from the phase 1 RMC-6236-001 trial in patients with non–small cell lung cancer harboring KRAS mutations and details the significance of these findings for patients within the KRAS G12X-mutant NSCLC population.

Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC

September 18th 2023

Melissa L. Johnson, MD, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan in patients with refractory small cell lung cancer, which she presented at the 2023 IASLC World Conference on Lung Cancer.

Dr Johnson on ABBV-011 in Small Cell Lung Cancer

July 20th 2023

Melissa L. Johnson, MD, discusses the development of the seizure-related homolog protein 6–targeting antibody-drug conjugate ABBV-011 and outcomes with this agent in patients with small cell lung cancer.

Dr Johnson on Domvanalimab, Zimberelimab, and Etrumadenant in NSCLC

June 8th 2023

Melissa L. Johnson, MD, discusses findings from the phase 2 ARC-7 trial in patients with previously untreated metastatic, PD-L1–high non–small cell lung cancer.

Dr Johnson on BL-B01D1 in Locally Advanced or Metastatic Solid Tumors

June 8th 2023

Melissa L. Johnson, MD, discusses findings from the phase 1 BL-B01D1-101 trial investigating the efficacy and safety of the EGFR- and HER3-directed antibody-drug conjugate BL-B01D1 in patients with locally advanced or metastatic solid tumors, including non–small cell lung cancer.

Dr. Johnson on the Evolution of Frontline Treatment in NSCLC

October 5th 2022

Melissa L. Johnson, MD, discusses the evolution of frontline treatment in non–small cell lung cancer.

Dr. Johnson on the Potential of TROP2 as a Target for All-Comers With Solid Tumors

October 29th 2021

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

Dr. Johnson on Datopotamab Deruxtecan in NSCLC With Actionable Genomic Alterations

October 15th 2021

Melissa L. Johnson, MD, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic alterations.

Dr. Johnson on the Promise of DS-7300 in SCLC and Other Advanced Solid Tumors

October 13th 2021

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

Dr. Johnson on the Clinical Potential of AMG 757 in SCLC

March 29th 2021

Melissa L. Johnson, MD, discusses the clinical potential of AMG 757 in patients with small cell lung cancer.

Dr. Johnson on the Results of the CITYSCAPE Trial in PD-L1+ NSCLC

May 29th 2020

Melissa L. Johnson, MD, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).

Dr. Johnson on the Future of Immunotherapy in Lung Cancer

May 27th 2017

Melissa L. Johnson, MD, medical oncologist, Sarah Cannon Research Institute, discusses potential immunotherapy regimens for patients with lung cancer.